T. Mills Kenneth's most recent trade in Regenxbio Inc was a trade of 225,000 Common Stock done at an average price of $13.1 . Disclosure was reported to the exchange on Jan. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.09 per share. | 27 Jan 2026 | 225,000 | 707,871 (1%) | 0% | 13.1 | 2,945,250 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2026 | 225,000 | 225,000 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.41 per share. | 27 Jan 2026 | 221,753 | 486,118 (1%) | 0% | 13.4 | 2,973,708 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 39,815 | 39,815 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 7,768 | 482,871 (1%) | 0% | 0 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2025 | 20,602 | 0 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Sale of securities on an exchange or to another person at price $ 7.91 per share. | 12 May 2025 | 20,602 | 475,103 (1%) | 0% | 7.9 | 163,046 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 12 May 2025 | 20,602 | 495,705 (1%) | 0% | 3.8 | 77,464 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2025 | 30,752 | 20,602 | - | - | Stock Options (Right to Buy) | |
| Regenxbio Inc | Kenneth T. Mills | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 27 Mar 2025 | 30,752 | 475,103 (1%) | 0% | 3.8 | 115,628 | Common Stock |
| Regenxbio Inc | Kenneth T. Mills | Director | 08 Aug 2024 | 36,316 | 0 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 08 Aug 2024 | 36,316 | 444,351 (1%) | 0% | 0.9 | 30,869 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 15,369 | 51,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 15,369 | 408,035 (1%) | 0% | 14.0 | 214,501 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 15,369 | 423,404 (1%) | 0% | 3.8 | 57,787 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 12,221 | 420,256 (1%) | 0% | 3.8 | 45,951 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 12,221 | 66,723 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 24 Jul 2024 | 12,221 | 408,035 (1%) | 0% | 13.8 | 168,433 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 2,210 | 78,944 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 2,210 | 408,035 (1%) | 0% | 13.8 | 30,440 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 2,210 | 410,245 (1%) | 0% | 3.8 | 8,310 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 200 | 408,035 (1%) | 0% | 13.8 | 2,752 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 200 | 81,154 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director | 16 Jul 2024 | 200 | 408,235 (1%) | 0% | 3.8 | 752 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 May 2024 | 15,000 | 81,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 May 2024 | 15,000 | 408,035 (1%) | 0% | 15.8 | 237,222 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 May 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 15 Apr 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 15 Apr 2024 | 15,000 | 96,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 15 Apr 2024 | 15,000 | 408,035 (1%) | 0% | 18.2 | 272,871 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 Mar 2024 | 15,000 | 111,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 Mar 2024 | 15,000 | 408,035 (1%) | 0% | 21.9 | 327,942 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 14 Mar 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 14 Feb 2024 | 15,000 | 423,035 (1%) | 0% | 3.8 | 56,400 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 14 Feb 2024 | 15,000 | 126,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 14 Feb 2024 | 10,348 | 408,035 (1%) | 0% | 16.9 | 174,723 | Common Stock | |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | 14 Feb 2024 | 4,652 | 418,383 (1%) | 0% | 16.5 | 76,626 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 16 Jan 2024 | 45,000 | 141,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | 16 Jan 2024 | 45,000 | 408,035 (1%) | 0% | 15.2 | 682,992 | Common Stock | |
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 16 Jan 2024 | 45,000 | 453,035 (1%) | 0% | 3.8 | 169,200 | Common Stock | |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | 02 Jan 2024 | 305,250 | 305,250 | - | - | Stock Options (Right to buy) | ||
| Regenxbio Inc | Mills T. Kenneth | Director, President and CEO | 02 Jan 2024 | 64,103 | 408,035 (1%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth Mills T. | Director, President and CEO | 02 Jan 2024 | 11,357 | 343,932 (0%) | 0% | 17.9 | 203,858 | Common Stock | |
| Regenxbio Inc | Mills Kenneth T. | Director, President and CEO | 19 Dec 2023 | 45,000 | 355,289 (0%) | 0% | 19.7 | 885,825 | Common Stock | |
| Regenxbio Inc | T. Mills Kenneth | Director, President and CEO | 19 Dec 2023 | 43,500 | 186,354 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | 19 Dec 2023 | 43,500 | 398,789 (1%) | 0% | 3.8 | 163,560 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 19 Dec 2023 | 1,500 | 36,316 | - | - | Stock Options (Right to Buy) | ||
| Regenxbio Inc | T. Kenneth Mills | Director, President and CEO | 19 Dec 2023 | 1,500 | 400,289 (1%) | 0% | 0.9 | 1,275 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 03 Jan 2023 | 264,932 | 264,932 | - | - | Stock Options (Right to buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 03 Jan 2023 | 54,753 | 355,289 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 03 Jan 2023 | 9,308 | 300,536 (0%) | 0% | 22.7 | 211,105 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 01 Jan 2022 | 170,188 | 170,188 | - | - | Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 01 Jan 2022 | 35,796 | 309,844 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 01 Jan 2022 | 3,636 | 274,048 (0%) | 0% | 32.7 | 118,897 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 02 Dec 2021 | 3,300 | 277,684 (0%) | 0% | 0 | Common Stock | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 08 Nov 2021 | 1,500 | 280,984 (0%) | 0% | 40 | 60,000 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 08 Nov 2021 | 1,500 | 229,854 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 08 Nov 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 27 Sep 2021 | 1,500 | 280,984 (0%) | 0% | 42.2 | 63,285 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 27 Sep 2021 | 1,500 | 231,354 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 27 Sep 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 35,000 | 280,984 (0%) | 0% | 45.1 | 1,578,850 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 33,146 | 232,854 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 33,146 | 314,130 (0%) | 0% | 3.8 | 124,629 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 3,000 | 266,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 3,000 | 280,984 (0%) | 0% | 40.0 | 120,060 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 3,000 | 283,984 (0%) | 0% | 3.8 | 11,280 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 1,854 | 37,816 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 13 Sep 2021 | 1,854 | 315,984 (0%) | 0% | 0.9 | 1,576 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 4,500 | 280,984 (0%) | 0% | 40.0 | 180,090 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 4,500 | 285,484 (0%) | 0% | 3.8 | 16,920 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 4,500 | 270,500 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 1,500 | 282,484 (0%) | 0% | 3.8 | 5,640 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 1,500 | 269,000 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 24 Jun 2021 | 1,500 | 280,984 (0%) | 0% | 40.3 | 60,375 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Feb 2021 | 1,500 | 280,984 (0%) | 0% | 40.8 | 61,155 | Common Stock | |
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Feb 2021 | 1,500 | 39,670 | - | - | Employee Stock Option (Right to Buy) | ||
| Regenxbio Inc | Kenneth T. Mills | Director, President and CEO | 25 Feb 2021 | 1,500 | 282,484 (0%) | 0% | 0.9 | 1,275 | Common Stock |